Filariasis: New drugs and new opportunities for lymphatic filariasis and onchocerciasis

Current Opinion in Infectious Diseases

Volumn 21, Issue 6, 2008, Pages 673-681

  Hoerauf, Achim ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Doxycycline; Filariasis; Hydrocele; Lymphedema; Wolbachia

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; PLACEBO; TETRACYCLINE;

BANCROFTIAN FILARIASIS; DISEASE COURSE; ENDEMIC DISEASE; FILARIASIS; HEALTH CARE; HUMAN; HYDROCELE; LYMPH VESSEL; LYMPHATIC FILARIASIS; LYMPHEDEMA; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PAIN; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASODILATATION; WOLBACHIA; WORM;

ANIMALS; DOXYCYCLINE; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; WUCHERERIA BANCROFTI;

EID: 57049102875     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328315cde7     Document Type: Review

References (72)

1. WHO. Meeting of the International Task Force for Disease Eradication-11 January 2007. Wkly Epidem Rec 2007; 82:197-208.
2. WHO. Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administrations in 2006. Wkly Epidem Rec 2007; 82:361-380.
3. Awadzi K, Attah SK, Addy ET, et al. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg 1999; 93:189-194.
4. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997; 75:491-503. This is still the standard review explaining the rationale for the MDA to eliminate lymphatic filariasis.
5. Noroes J, Dreyer G, Santos A, et al. Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans R Soc Trop Med Hyg 1997; 91:78-81.
6. Critchley J. Albendazole for lymphatic filariasis. Cochrane Database Syst Rev 2005:CD003753.
7. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005; 6:179-200. This and the preceding review are important for the assessment to what extent ALB confers additive efficacy to DEC against lymphatic filariasis.
8. Dreyer G, Addiss D, Williamson J, Noroes J. Efficacy of co-administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2006; 100:1118-1125.
9. Technical Advisory Group on the Global Elimination of Lymphatic Filariasis (TAG-ELF). Report of the Fifth Meeting Geneva, Switzerland, 3-6 February 2004. Geneva: WHO; 2004:1-37.
10. Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/ sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006; 2:e92. This study shows that Wolbachia depletion is associated with a reduction in the levels of vascular endothelial growth factors essential for lymphangiogenesis, and precedes both a reduction in lymph vessel dilation and improvement of lymphatic pathology.
11. Debrah A, Mand S, Marfo-Debrekyei Y, et al. Macrofilaricidal activity after four weeks doxycycline treatment of Wuchereria bancrofti. Trop Med Int Health 2007; 12:1433-1441.
12. Hoerauf A, Volkmann L, Paehle K, et al. Targeting of Wolbachia in Litomosoides sigmodontis: comparison of tetracycline with chloramphenicol, macrolides and ciprofloxacin. Trop Med Int Health 2000; 5:275-279.
13. Hoerauf A, Specht S, Büttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis. Med Microbiol Immunol 2008; 197:295-311. This trial showed that doxycycline confers 60% macrofilaricidal activity against O. volvulus worms and renders doxycycline the first macrofilaricidal treatment besides the toxic suramin.
14. Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity following doxycycline treatment of Wuchereria bancrofti: a double-blind randomised controlled trial. Lancet 2005; 365:2116-2121. This trial is the first to show that antiwolbachial chemotherapy is macrofilaricidal in filariasis.
15. Basanez MG, Pion SD, Churcher TS, et al. River blindness: a success story under threat? PLoS Med 2006; 3:e371.
16. Fiftieth World Health Assembly. Elimination of lymphatic filariasis as a public health problem. Geneva, Switzerland: World Health Assembly; 1997. pp. 1-2.
17. Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv Parasitol 2006; 61:349-394. This is an extensive review on the developments in onchocerciasis over the past 10 years.
18. Hodgkin C, Molyneux DH, Abiose A, et al. The future of onchocerciasis control in Africa. PLoS Negl Trop Dis 2007; 1:e74.
19. WHO regional office Ouagadougou. Onchocerciasis control in Africa. Geneva: World Health Organisation; 2006. pp. 1-4.
20. Eezzuduemhoi D, Wilson D. Onchocerciasis. http://www.emedicine.com/ OPH/topic709.htm. [Accessed 3 July 2008].
21. WHO. Report from the 16th Interamerican Conference on Onchocerciasis, Antigua, Guatemala. Wkly Epidem Rec 2007; 82:309-316.
22. The Carter Center. Summary of the Tenth Meeting of the International Task Force for Disease Eradication, January 11, 2007. Atlanta: The Carter Center; 2007. pp. 1-4.
23. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the Eradicability of Onchocerciasis. Filaria J 2003; 2:2.
24. Esterre P, Richart C, Sechan Y, Nguyen NL. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop Med Int Health 2001; 6:190-195.
25. Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98:231-249.
26. Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007; 369:2021-2029. This report has extended the findings of [25] and demonstrated that the suboptimal performance of IVM is more widespread in the area than originally thought.
27. WHO. Technical Advisory Group on the global elimination of lymphatic filariasis (TAG-ELF): report of the fifth meeting, Geneva, Switzerland, 3-6 February 2004. http://whqlibdoc.who.int/hq/2004/CDS_CPE_CEE_2004.42.pdf. [Accessed 3 July 2008].
28. Kläger SL, Whitworth JA, Downham MD. Viability and fertility of adult Onchocerca volvulus after 6 years of treatment with ivermectin. Trop Med Int Health 1996; 1:581-589.
29. Duke BO. Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms. Parasitology 2005; 130:447-453.
30. Dreyer G, Addiss D, Santos A, et al. Direct assessment in vivo of the efficacy of combined single-dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 1998; 92:219-222.
31. Kshirsagar NA, Gogtay NJ, Garg BS, et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India. Trans R Soc Trop Med Hyg 2004; 98:205-217.
32. Helmy H, Weil GJ, Ellethy AS, et al. Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans R Soc Trop Med Hyg 2006; 100:656-662. This study compared a single-dose vs. a 7-day course of a DEC and ALB combination, showing that the longer treatment is superior at clearing microfilariae but equivalent at clearing circulating antigen, a marker for macrofilaricidal activity.
33. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today 2000; 16:544-548.
34. Noroes J, Addiss D, Cedenho A, et al. Pathogenesis of filarial hydrocele: risk associated with intrascrotal nodules caused by death of adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2003; 97:561-568.
35. Babu BV, Rath K, Kerketta AS, et al. Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India. Trans R Soc Trop Med Hyg 2006; 100:464-469.
36. Büttner D, Albiez EJ, Parow D. Parasitological studies on Onchocerca volvulus eight years after interruption of the transmission in Upper Volta. Bull Soc Path Exot Filiales 1983; 76:669-675. This study shows that in the absence of ongoing transmission, the rate of dead worms in nodules is significantly higher than in nodules from patients that live in an area with ongoing transmission.
37. Awadzi K, Addy ET, Opoku NO, et al. The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole. Trop Med Parasitol 1995; 46:213-220.
38. Critchley J, Addiss D, Ejere H, et al. Albendazole for the control and elimination of lymphatic filariasis: systematic review. Trop Med Int Health 2005; 10:818-825.
39. Jayakody RL, de Silva CSS, Weerasinghe WMT. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Trop Biomed 1993; 10:19-24.
40. Hoerauf A, Nissen-Pähle K, Schmetz C, et al. Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertility. J Clin Invest 1999; 103:11-18.
41. Bandi C, McCall JW, Genchi C, et al. Effects of tetracycline on the filarial worms Brugia pahangi and Dirofilaria immitis and their bacterial endosymbionts Wolbachia. Int J Parasitol 1999; 29:357-364.
42. Fenollar F, Maurin M, Raoult D. Wolbachia pipientis growth kinetics and susceptibilities to 13 antibiotics determined by immunofluorescence staining and real-time PCR. Antimicrob Agents Chemother 2003; 47:1665-1671.
43. Makepeace BL, Rodgers L, Trees AJ. Rate of elimination of Wolbachia pipientis by doxycycline in vitro increases following drug withdrawal. Antimicrob Agents Chemother 2006; 50:922-927.
44. Townson S, Hutton D, Siemienska J, et al. Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi. Ann Trop Med Parasitol 2000; 94:801-816.
45. Townson S, Tagboto S, McGarry HF, et al. Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro. Filaria J 2006; 5:4. This study describes a method of in-vitro testing of antifilarial drugs at a higher throughput.
46. Rao R, Weil GJ. In vitro effects of antibiotics on Brugia malayi worm survival and reproduction. J Parasitol 2002; 88:605-611.
47. Volkmann L, Fischer K, Taylor M, Hoerauf A. Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop Med Int Health 2003; 8:392-401.
48. Rao RU, Moussa H, Weil GJ. Brugia malayi: effects of antibacterial agents on larval viability and development in vitro. Exp Parasitol 2002; 101:77-81.
49. Hoerauf A, Marfo-Debrekyei Y, Buttner M, et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus. Parasitol Res 2008; 103:279-286.
50. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355:1242-1243.
51. Hoerauf A, Mand S, Adjei O, et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001; 357:1415-1416.
52. Hoerauf A, Marfo-Debrekyei Y, Büttner M, et al. Efficacy of five weeks doxycycline treatment on adult Onchocerca volvulus. Parasitol Res (in press).
53. Turner JD, Mand S, Debrah AY, et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006; 42:1081-1089.
54. Supali T, Djuardi Y, Pfarr KM, et al. Doxycycline treatment of Brugia malayi- infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008; 46:1385-1393. This study shows that after Wolbachia depletion from microfilariae by doxycycline, rapid killing of microfilariae by DEC provokes less inflammatory immune responses and less clinical adverse reactions.
55. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003; 5:261-273.
56. Pfarr K, Hoerauf A. Wolbachia endosymbionts: an Achilles heal of filarial nematodes. In: Hoerauf A, Rao R, editors. Wolbachia: a bug's life in another bug. Karger; 2007.
57. Awadzi K. Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis. Filaria J 2003; 2 Suppl 1:S6. This is a very comprehensive overview of adverse reactions by drugs tested against human onchocerciasis.
58. Mand S, Supali T, Djuardi J, et al. Detection of adult Brugia malayi filariae by ultrasonography in humans in India and Indonesia. Trop Med Int Health 2006; 11:1375-1381.
59. Dreyer G, Addiss D, Roberts J, Noroes J. Progression of lymphatic vessel dilatation in the presence of living adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2002; 96:157-161.
60. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8:464-478.
61. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438:946-953.
62. Halin C, Tobler NE, Vigl B, et al. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 2007; 110:3158-3167.
63. Debrah A, Mand S, Toliat MR, et al. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 2007; 77:601-608. This study shows for the first time a highly significant genetic association of a SNP (in a gene relevant for angiogenesis) with hydrocele development.
64. Dreyer G, Addiss D, Dreyer P, Noroes J. Basic lymphoedema management. Treatment and prevention of problems associated with lymphatic filariasis. Hollis, New Hampshire, USA: Hollis Publishing Company; 2002. This book is the most comprehensive clinical overview of lymphoedema and its management.
65. Cuenco KT, Halloran ME, Louis-Charles J, Lammie PJ. A family study of lymphedema of the leg in a lymphatic filariasis-endemic area. Am J Trop Med Hyg 2004; 70:180-184.
66. Cuenco KT, Halloran ME, Lammie PJ. Assessment of families for excess risk of lymphedema of the leg in a lymphatic filariasis-endemic area. Am J Trop Med Hyg 2004; 70:185-190.
67. Keiser PB, Coulibaly Y, Kubofcik J, et al. Molecular identification of Wolbachia from the filarial nematode Mansonella perstans. Mol Biochem Parasitol 2008; 160:123-128.
68. Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res 2008 [Epub ahead of print].
69. Richards FO Jr, Amann J, Arana B, et al. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin. Am J Trop Med Hyg 2007; 77:878-882.
70. Trees AJ, Graham SP, Renz A, et al. Onchocerca ochengi infections in cattle as a model for human onchocerciasis: recent developments. Parasitology 2000; 120 Suppl:S133-S142.
71. Boussinesq M. Onchocerciasis control: biological research is still needed. Parasite 2008; 15:510-514.
72. Hudson A, Nwaka S. The concept paper on the helminth drug initiative. Onchocerciasis/lymphatic filariasis and schistosomiasis: opportunities and challenges for the discovery of new drugs/diagnostics. Expert Opin Drug Discov 2007; 2:S3-S7.